Alkermes Says U.S. FDA Accepts Review Of NDA For ALKS 5461 - Quick Facts

Alkermes plc (ALKS) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461. FDA's target action date for the ALKS 5461 NDA is January 31, 2019.

from RTT - Biotech https://ift.tt/2vhl2D4
via IFTTT